Hudson Regional Health system has launched. Leaders announced the creation of the four-hospital health system headquartered in Secaucus May 27. The network incorporates Hudson Regional Hospital, Christ Hospital in Jersey City, Hoboken University Medical Center, Bayonne Medical Center and more than 70 affiliated practice locations. The announcement follows the wrapping up of legal hurdles pertaining to the bankruptcy of CarePoint Health System, on which NJBIZ has extensively reported. In April, a federal bankruptcy court cleared the way for the creation of the new health system. On May 22, the plan went into effect.
More than a decade after its Google Glass flopped, Google is developing a new generation of augmented reality glasses designed to merge the physical and digital worlds.
Before the Trump administration, grant cancellations were a rarity — often reserved for cases of outright fraud or data manipulation. But, just months into the current administration, some 2,100 NIH grants, totaling around $9.5 billion, have been terminated. For some time, there was no record of the devastation on the scientific community.
Twenty-seven minutes into a town hall with staff last week, NIH Director Dr. Jay Bhattacharya acknowledged that he was going to get into uncomfortable territory. 'This one's a tough one for me,' Bhattacharya told the audience of researchers and other NIH employees gathered in an auditorium at the biomedical research agency's headquarters in Bethesda, Maryland, last Monday, before introducing one of the most divisive topics in science.
A paradigm shift in the way we treat spinal injuries is now in sight, with the world's first regenerative cell therapy being granted approval for a registrational Phase I clinical trial. It's a historical milestone that could successfully treat what has, until now, been an incurable condition.
Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.